Gotrade News - Odyssey Therapeutics priced its upsized initial public offering at $18 per share on Thursday, the top of its $16 to $18 marketed range, and will begin trading on the Nasdaq Capital Market on May 8, 2026 under the ticker ODTX. The Boston-based biopharmaceutical company sold 15.5 million shares in the primary offering, raising roughly $279 million before fees.
According to Investing.com, the company also completed a concurrent private placement of 1.388 million shares to an affiliate of TPG Life Sciences Innovations at the same $18 price. Combined with the public offering, expected gross proceeds rise to approximately $304 million before underwriting fees and expenses.
A clean upsize at the top of the range
The deal was upsized during marketing, a signal that demand outpaced the original book. Underwriters also received a 30-day option to purchase up to 2.325 million additional shares at $18, which could push proceeds higher if exercised in full.
J.P. Morgan, TD Cowen, and Cantor served as joint lead underwriters. Wedbush PacGrow and Oppenheimer & Co. acted as co-lead managers. The U.S. Securities and Exchange Commission declared Odyssey's Form S-1 effective on May 7, 2026, with the offering expected to close on or about May 11.
What Odyssey actually does
Odyssey Therapeutics, founded in 2021, develops treatments for autoimmune and inflammatory diseases. Its lead clinical candidate, OD-001, is in mid-stage trials for ulcerative colitis, a chronic inflammatory bowel condition with a large unmet-need patient population.
Investing.com reported that the company had previously raised approximately $726.5 million from more than 30 investors across multiple private rounds. That makes ODTX one of the more heavily capitalized biotechs to reach the public market in 2026.
CEO Dr. Gary D. Glick is a recognizable name in biotech founder circles. He previously founded Scorpion Therapeutics, which Eli Lilly agreed to acquire in 2025 for up to $2.5 billion. The track record likely contributed to the order book strength that allowed the upsize.
Use of proceeds and pipeline runway
The company plans to deploy IPO proceeds primarily toward clinical development of OD-001 and general corporate purposes. With $304 million in gross proceeds layered on top of the prior $726.5 million private war chest, Odyssey has multi-year runway to push OD-001 through later-stage trials without immediate refinancing pressure.
That cash position matters because mid-stage autoimmune programs typically need 24 to 36 months and several hundred million dollars to reach a registrational data readout. Odyssey is now funded for that path.
Why this IPO matters for the broader biotech tape
The 2026 biotech IPO window has been notably more active than 2024 and 2025. Investing.com cited a revival driven by policy shifts under the current administration and changes at the FDA, which have improved investor visibility into clinical timelines.
A clean upsize that prices at the top of the range, with a TPG anchor in the private placement, is the kind of print that other late-stage private biotechs benchmark against. If ODTX trades well in its first sessions, expect the queue of biotech S-1 filers behind it to accelerate their own launches.
Risks to flag
Two things worth tracking. First, OD-001 is still mid-stage, so a single negative readout in ulcerative colitis would compress the valuation quickly. Second, post-IPO biotech volatility is structurally high, and the $18 pricing reflects an order book on a specific day, not a steady-state valuation.
For investors looking at ODTX in the secondary market, the watch items are the OD-001 trial readout cadence and the cash-runway trajectory at each quarterly report.
Sources:
